Bonita David P 4

What Happened

• Bonita David P, reported as a 10% owner of Prelude Therapeutics (PRLD), received an award of 38,000 derivative shares/options on 2026-06-09. The grant shows an acquisition price of $0.00 (no cash paid) and is reported as a derivative award rather than an open-market purchase or sale.
• The award will vest in full on the earlier of (a) the issuer’s next annual stockholder meeting or (b) the one-year anniversary of the grant date, subject to the Reporting Person’s continued service on each vesting date (see footnote F1). Per footnote F2, the Reporting Person is obligated to transfer any securities or economic benefits from these awards to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will allocate them to OrbiMed Private Investments VI, LP.

Key Details

• Transaction date: 2026-06-09; Filing date: 2026-06-10 (filed the next day).
• Instrument: Award of 38,000 derivative shares/options; acquisition price reported $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 describes vesting schedule (next annual meeting or one-year anniversary, subject to continued service). F2 states the Reporting Person must transfer the securities/economic benefits to OrbiMed entities for allocation to OrbiMed Private Investments VI, LP.
• Filing timeliness: Filed promptly the day after the transaction (no late filing indicated).

Context

• This was an award of derivative securities (options/awards) rather than a cash purchase or sale. Awards like this often reflect compensation or internal allocation arrangements and may not signal immediate market sentiment.
• Because the Reporting Person is a 10% owner with an obligation to transfer the award to OrbiMed-related entities, this appears to be an institutional allocation/arrangement rather than a personal trading decision by an executive.